In today’s episode, Chad sits down with Angela Stoyanovitch, a director of business development at BioAgilytix and founder of the Legal Drugs podcast. She’s a podcaster, veteran business developer, social media strategist and consultant who kicked off her career in research who has held business development roles across pre-clinical research, bioanalysis and in basic research. They discuss how she fell in love with the service side of research and her advice for others interested the drug industry.

In today&rsquo;s episode, Chad sits down with Angela Stoyanovitch, a director of business development at BioAgilytix and founder of the Legal Drugs podcast. She&rsquo;s a podcaster, veteran business developer, social media strategist and consultant who kicked off her career in research who has held business development roles across pre-clinical research, bioanalysis and in basic research. They discuss how she fell in love with the service side of research and her advice for others interested the drug industry.

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Molecular Moments Podcast

Welcome to the Molecular Moments podcast hosted by the scientific experts at BioAgilytix Labs! Whether you’re curious about what goes on at BioAgilytix or about the folks behind the lab coats, we’ve found a way to bring biologics closer to home. Each week, we chat with global experts, colleagues, and thought leaders who influence the pharmaceutical industry in biotherapeutics and beyond.

Molecular Moments

Angela Stoyanovitch talks Detroit Pride, Legal Drugs, and the Google of CROs

On this episode of Molecular Moments, Dr. Amanda Hays chats with BioAgilytix scientists Dr. Shashank Gorityala, Associate Director of LC/MS Operations from our Durham lab, and Dr. Ben Nie, Scientist III from our San Diego lab. They delve into LC/MS evolution, tech strides, and its role in large molecule bioanalysis. Discover the benefits of LC/MS for protein and biomarker quantification, different workflows, and the challenges of transitioning from small to large molecules. The experts also spill
insights on internal standards, acceptance criteria, and clever sample pretreatment techniques to conquer signal suppression.

On this episode of Molecular Moments, Dr. Amanda Hays chats with BioAgilytix scientists Dr. Shashank Gorityala, Associate Director of LC/MS Operations from our Durham lab, and Dr. Ben Nie, Scientist III from our San Diego lab. They delve into LC/MS evolution, tech strides, and its role in large molecule bioanalysis. Discover the benefits of LC/MS for protein and biomarker quantification, different workflows, and the challenges of transitioning from small to large molecules. The experts also spill insights on internal standards, acceptance criteria, and clever sample pretreatment techniques to conquer signal suppression.

Drs. Shashank Gorityala, Ben Nie, and Amanda Hays talk LC/MS bioanalysis, platforms, matrices, workflows, and regulations.

On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to craft software that frees their clients to do what they do best: advance cutting-edge technology, improve lives, and effect social change. They discuss their shared passion for problem-solving and how the right mindset helps find solutions to new issues that arise.

They talk about the role of data privacy and security with big data and what steps you can take to reconcile and harmonize data. Adam lays out several common problems encountered with large datasets, including inconsistencies, and how to go about solving them. He discusses the value his company provides by breaking down big problems into smaller independent issues and how by moving fast and asking for feedback, his team can deliver a variety of solutions to clients with many different needs in all different stages of the process. 

On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of <a href="https://scimed.io/" data-saferedirecturl="https://www.google.com/url?q=https://scimed.io/&amp;source=gmail&amp;ust=1680278640603000&amp;usg=AOvVaw1L7Ex10OB3Kr35BsrWKVcI">SciMed</a>, whose mission is to craft software that frees their clients to do what they do best: advance cutting-edge technology, improve lives, and effect social change. They discuss their shared passion for problem-solving and how the right mindset helps find solutions to new issues that arise.
They talk about the role of data privacy and security with big data and what steps you can take to reconcile and harmonize data. Adam lays out several common problems encountered with large datasets, including inconsistencies, and how to go about solving them. He discusses the value his company provides by breaking down big problems into smaller independent issues and how by moving fast and asking for feedback, his team can deliver a variety of solutions to clients with many different needs in all different stages of the process.

On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to craft software that frees their clients to do what they do best: advance cutting-edge technology, improve lives, and effect social change. They discuss their shared passion for problem-solving and how the right mindset helps find solutions to new issues that arise.

Adam Stasio Talks, Large Data Sets, Breaking Down Problems, and Tech-Driven Solutions

On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at the National Science Foundation (NSF) and a Willa Cather Professor of Chemistry at the University of Nebraska-Lincoln, and co-lead of the Nebraska Drug Discovery & Development Pipeline. David shares how he got his early beginnings in science as an undergrad studying endocrinology at the University of Chicago, going to Switzerland with his Ph.D. advisor to work at a chemistry biology interface, and later attending Yale to understand how to make molecules better. 

Chad and David also discuss the National Strategic Institute in Nebraska and David’s involvement with the program to research medical countermeasures for Acute Radiation Syndrome (ARS), the difficulty of testing drugs for prophylaxis treatments, and the importance of getting the most out of the NSF. They reminisce about when David was supportive of Chad’s pursuit of his Ph.D. at the University of Nebraska. David talks about some exciting work he’s doing with enzymes that came about as a result of talking to someone while waiting for a slow elevator, how higher learning has changed over the years, and running the Lincoln Marathon. 

On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at the National Science Foundation (NSF) and a Willa Cather Professor of Chemistry at the University of Nebraska-Lincoln, and co-lead of the Nebraska Drug Discovery &amp; Development Pipeline. David shares how he got his early beginnings in science as an undergrad studying endocrinology at the University of Chicago, going to Switzerland with his Ph.D. advisor to work at a chemistry biology interface, and later attending Yale to understand how to make molecules better. Chad and David also discuss the National Strategic Institute in Nebraska and David’s involvement with the program to research medical countermeasures for Acute Radiation Syndrome (ARS), the difficulty of testing drugs for prophylaxis treatments, and the importance of getting the most out of the NSF. They reminisce about when David was supportive of Chad’s pursuit of his Ph.D. at the University of Nebraska. David talks about some exciting work he’s doing with enzymes that came about as a result of talking to someone while waiting for a slow elevator, how higher learning has changed over the years, and running the Lincoln Marathon.

Angela Stoyanovitch talks Detroit Pride, Legal Drugs, and the Google of CROs

Molecular Moments Podcast

In 1 playlist(s)

Molecular Moments

Social links

Follow podcast

Recent clips